Abstract:© Arnold 1998 0267–6591(98)PM167ED The modern hospice and palliative care movement developed during the 1960s and 1970s as a response to the unmet needs of terminally ill patients and their families.1 This British initiative soon became an international endeavour. Regular local, national and international meetings, six peerreviewed journals and a comprehensive multiauthored textbook provide evidence of the increasing body of knowledge in the field.2 Palliative care is currently provided in multiple settings, including acute care hospitals, cancer centres, hospices and at home by an increasing number of health care professionals. Palliative care, however, has only been partially successful in two areas. One is the integration with academic medicine. As a result, undergraduate and postgraduate palliative medicine education is either not available or is insufficient in most medical schools around the world, although a number of curricula have been produced.3 In addition, palliative care clinicians have major difficulties in conducting research without the methodological support available to academic physicians.4 The second problem area is the partial insertion of palliative care programmes within the health care system. This has made funding difficult for programmes and professionals, and has limited patient and family access to palliative care services. The lack of complete integration within the health care system is concerning because of the expected increase in the number of cancer deaths of 50% and 70% in developed and developing countries respectively during the next decade, and the general ageing of the world population.5 If the number of available programmes and professionals does not increase accordingly, access to palliative care will progressively decrease. In times of decreasing health care budgets worldwide, maintaining or expanding existing programmes requires palliative care to demonstrate that it can improve specific clinical outcomes in patients and families. In other words, does palliative care work? Is it better for patients and their families to receive palliative care as compared to conventional care? The great majority of those working in palliative care would feel that it is obvious that palliative care is effective. However, a recent systematic review of palliative cancer care identified a minimal number of published studies.6 Both patient populations and the nature of the palliative interventions were poorly defined in such studies. In addition, the outcome measures were very different, making the comparison of results difficult. These findings therefore suggest that we need better effectiveness studies. Palliative care also needs to show how the cost of our interventions compares with conventional care. Economic evaluations of health care have traditionally attempted to establish differences in costs of interventions assumed to be of identical efficacy in all relevant aspects (cost-minimization analysis) or of interventions that are likely to have different outcomes (cost effectiveness, cost-benefit, and cost-utility analysis).7 The latter have been used in the economic evaluation of interventions such as renal or cardiac transplantation, screening of prostate or breast cancer, and immunizations. The effectiveness outcomes of such economic evaluations include quality-adjusted life-years, lifeyears gained, disability days saved, etc. It has been suggested that the threshold value ranges from $20 000 to $100 000 (Canadian dollars) per qualityadjusted life-year.8 These effectiveness outcomes are inappropriate for economic evaluations in palliative care. It is, therefore, important to define patient, family, and society related benefits of palliative care interventions that can be used in economic evaluations. Editorial

Highly Potential-Resolved Anodic Electrochemiluminescence Multiplexing Immunoassay with CuInS2@ZnS Nanocrystals and [ru(bpy)2(dcbpy)]2+ As Emitters

Potential-Resolved Multicolor Electrochemiluminescence for Multiplex Immunoassay in a Single Sample.

Cost effectiveness in palliative care

Potential-Resolved Electrochemiluminescence for Determination of Two Antigens at the Cell Surface

Potential-resolved Electrochemiluminescence for Simultaneous Determination of Multiplex Bladder Cancer Markers

Coreactant-Free and Direct Electrochemiluminescence from Dual-Stabilizer-Capped InP/ZnS Nanocrystals: A New Route Involving n-Type Luminophore.

Ratiometric electrochemiluminescent strategy regulated by electrocatalysis of palladium nanocluster for immunosensing.

Potential-resolved electrochemiluminescence biosensor for simultaneous determination of multiplex miRNA

Coupled Fluorometer-Potentiostat System and Metal-Free Monochromatic Luminophores for High-Resolution Wavelength-Resolved Electrochemiluminescent Multiplex Bioassay

Surface-Enhanced Electrochemiluminescence Imaging for Multiplexed Immunoassays of Cancer Markers in Exhaled Breath Condensates

Aggregation-induced electrochemiluminescence based on intramolecular charge transfer and twisted molecular conformation for label-free Immunoassay

Rechargeable Battery-Based Constant-Potential Electroluminescence Multiplexed Immunoassay on Single Working Electrode for Sequentially Anodic and Cathodic Detection Through a Self-Assembly Toggle Switch

Electrochemiluminescent Imaging for Multi-immunoassay Sensitized by Dual DNA Amplification of Polymer Dot Signal.

Bipolar silica nanochannel array for dual-mode electrochemiluminescence and electrochemical immunosensing platform

Multi-Segmented Cds-Au Nanorods For Electrochemiluminescence Bioanalysis

Dual amplification electrochemiluminescence of carbonized polymer dots embedded in the metal-organic framework with low trigger potential and nanoconfinement enhancement for sensitive CYFRA21-1 immunoassay

Potential-resolved ratiometric electrochemiluminescence detection for prostate-specific antigen based on CdS nanocrystals modified on carbon nanotubes and luminol functionalized nanocomposites

Near-Infrared Electrochemiluminescence of Dual-Stabilizer-Capped Au Nanoclusters for Immunoassays

Bidirectional electrochemiluminescence color switch: An application in detecting multi-markers of prostate cancer.

Surface Defect-Involved and Single-Color Electrochemiluminescence of Gold Nanoclusters for Immunoassay.

Particle Size-Controlled Oxygen Reduction and Evolution Reaction Nanocatalysts Regulate Ru(bpy)32+'s Dual-potential Electrochemiluminescence for Sandwich Immunoassay